Further, early bone loss and serotonin deficiency in Alzheimer’s may tell us something very important about how we approach diagnosis and treatment, the researchers noted.

“Routine assessment of bone density could serve as a useful biomarker for Alzheimer’s risk in ageing population,” said lead author Christine Dengler-Crish, Assistant Professor at Northeast Ohio Medical University(Neomed) in the US.

“The findings of this study motivate us to explore the serotonin system as a potential new therapeutic target for this devastating disease,” Dengler-Crish added.